Development of noncytotoxic peptide-based antibiotic derivatives against multidrug-resistant Gram-negative bacteria

The emergence and dissemination of antibiotic resistance is an escalating public health issue that requires immediate interventions. Among the essential agents in combating bacterial infections are peptide-based antibiotics. These naturally occurring or synthetic molecules exert potent antibacterial activity through various mechanisms such as membrane disruption, inhibition of cell wall synthesis, and immunomodulation. Despite their therapeutic potential, the clinical usage of these antibiotics has been limited due to associated systemic toxicity. Moreover, their efficacy is continuously challenged by the increasing prevalence of resistant bacteria. In the proposed project, targeted structural modifications of peptide-based antibiotics will be explored to improve safety, while enhancing potency against clinically relevant and resistant pathogens. The findings of this study will guide the optimization of next-generation antibiotics with desirable pharmacological properties, as well as inform the design of other therapeutic agents. Furthermore, this collaboration will advance the scientific profile of both universities by directly contributing to public health priorities, addressing the global problem of antibiotic resistance.

Faculty Supervisor:

Frank Schweizer

Student:

Partner:

Leiden University

Discipline:

Life Sciences

Sector:

Education

University:

University of Manitoba

Program: